Insider Selling: BeOne Medicines (NASDAQ:ONC) SVP Sells $102,300.00 in Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) SVP Chan Henry Lee sold 341 shares of the business’s stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $300.00, for a total value of $102,300.00. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Chan Henry Lee also recently made the following trade(s):

• On Wednesday, February 4th, Chan Henry Lee sold 1,660 shares of BeOne Medicines stock. The shares were sold at an average price of $349.52, for a total value of $580,203.20.
• On Wednesday, January 7th, Chan Henry Lee sold 664 shares of BeOne Medicines stock. The shares were sold at an average price of $331.76, for a total value of $220,288.64.

BeOne Medicines Stock Down 0.4%

ONC opened at $284.05 on Monday. BeOne Medicines Ltd. – Sponsored ADR has a one year low of $196.45 and a one year high of $385.22. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.08 and a current ratio of 3.41. The stock’s fifty day moving average is $334.52 and its 200-day moving average is $329.90. The company has a market capitalization of $31.15 billion, a PE ratio of 112.72 and a beta of 0.53.

BeOne Medicines (NASDAQ:ONC) last released its earnings results on Thursday, February 26th. The company reported $0.58 EPS for the quarter, missing analysts’ consensus estimates of $1.60 by ($1.02). The business had revenue of $1.50 billion during the quarter, compared to the consensus estimate of $1.45 billion. BeOne Medicines had a return on equity of 10.70% and a net margin of 5.37%. On average, equities analysts predict that BeOne Medicines Ltd. – Sponsored ADR will post -5.82 EPS for the current fiscal year.

Institutional Trading of BeOne Medicines

Several institutional investors have recently made changes to their positions in ONC. EFG International AG purchased a new position in BeOne Medicines during the fourth quarter valued at approximately $25,000. Anchor Investment Management LLC purchased a new stake in BeOne Medicines in the 2nd quarter worth approximately $26,000. Leonteq Securities AG acquired a new stake in shares of BeOne Medicines during the 4th quarter valued at $35,000. Daiwa Securities Group Inc. acquired a new stake in shares of BeOne Medicines during the 2nd quarter valued at $35,000. Finally, CWM LLC grew its holdings in shares of BeOne Medicines by 32.8% during the 4th quarter. CWM LLC now owns 158 shares of the company’s stock valued at $48,000 after acquiring an additional 39 shares in the last quarter. 48.55% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Sanford C. Bernstein raised BeOne Medicines from a “hold” rating to an “outperform” rating and set a $414.00 target price for the company in a report on Monday, January 12th. Barclays lifted their price target on BeOne Medicines from $394.00 to $405.00 and gave the stock an “overweight” rating in a research note on Friday, February 27th. Royal Bank Of Canada upped their price objective on shares of BeOne Medicines from $417.00 to $425.00 and gave the company an “outperform” rating in a research note on Thursday, February 26th. Truist Financial raised their target price on shares of BeOne Medicines from $400.00 to $412.00 and gave the stock a “buy” rating in a report on Friday, February 27th. Finally, Wall Street Zen downgraded shares of BeOne Medicines from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 28th. Eleven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $401.00.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.